Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Gene Therapy for Cancer and Restenosis Applications
View Prospective Grant of a Partial Exclusive License: Recombinant Heregulin PE-40 Toxin Cancer Therapeutics Which Bind to the Ligand Binding Site of the erbB3 and/or erbB4 Proteins
View National Institute of Environmental Health Sciences: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Application of Highly Potent and Ultraselective greek-d Opioidmimetic Peptide Antagonists for Biochemical, Pharmacological, Clinical and Therapeutic Studies Capability statements must be received by NIH on, or before May 21, 1996.
View National Heart, Lung, and Blood Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Lymphocyte ADP-Ribosyltransferase and its Corresponding Hydrolase as a Potential Target for Therapeutic Intervention in Diseases of the Immune System
View Prospective Grant of Exclusive License: Cartilage-Derived Morphogenetic Proteins
View Opportunity For Licensing: Sequence Modification of Oligonucleotide Primers to Manipulate Non-Templated Nucleotide Addition
View Prospective Grant of Exclusive License: Activity Dependent Neurotropic Factor
View National Institute of Allergy and Infectious Diseases: Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Influenza A PB2 Gene Technology License applications must be received on or before March 11, 1996. CRADA proposals should be received on or before April 11, 1996 for priority consideration. However, CRADA proposals submitted thereafter will be considered until a suitable CRADA Collaborator is selected.
View Prospective Grant of Exclusive License: Antibacterial Therapy With Bacteriophage Genotypically Modified to Delay Inactivation by the Host Defense System
View Prospective Grant of Exclusive License: Biomedical Uses of CPX (8-Cyclopentyl-1,3-Dipropylxanthine) and Related Compounds for Cystic Fibrosis and Other Human Diseases
View Prospective Grant of Exclusive License: Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods
View National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Homoharringtonine as an Anticancer Agent In view of the important priority of developing new drugs for the treatment of cancer, proposals must be received at the above
View Prospective Grant of Exclusive License: Veterinary Vaccine and Therapeutic Uses of Bartonella Henselae (Formerly Rochalimaea Henselae) Organisms
View Prospective Grant of Exclusive License: Immunologic Enhancement With Intermittent Interleukin-2 Therapy
View Prospective Grant of Exclusive License: Tumor Infiltrating Lymphocytes as a Treatment Modality for Human Cancer
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of New Types of Therapeutic Compounds for Acquired Immunodeficiency Syndrome (AIDS) and Other Human and Animal Diseases of Retroviral Etiology Identified Using Novel Screening Assays In view of the high priority for developing new drugs for the treatment of HIV infection, interested parties should notify the NCI Office of Technology Development in writing no later than sixty (60) days from the date of this announcement. Respondents will then be provided an additional ninety (90) days for submitting formal CRADA proposals.
View Prospective Grant of Exclusive License: Novel Neutrophil Chemotactic Factor, Cloned cDNA and Monoclonal Antibodies Thereto
View Prospective Grant of Exclusive License: Mouse Monoclonal Antibodies Specific for Normal Primate Tissue, Malignant Human Cultured Cell Lines and Human Tumors
View Prospective Grant of Exclusive License: Delta-Like Gene Expressed in Neuroendocrine Tumors
View Government-Owned Inventions; Availability for Licensing
View National Institute of Environmental Health Sciences: Opportunity for a Cooperative Research and Development Agreement (CRADA) for Development of Antibodies to the Cancer Metastasis Suppressor Gene KAI1 Capability statements must be received by NIH on or before September 18, 1995.
View Warren Grant Magnuson Clinical Center: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of High Resolution PET Scanner Using Scintillation Cameras Interested parties should notify this office in writing by September 11, 1995. Respondents will then be given an additional sixty (60) days for filing a formal proposal.
View Opportunity for Licensing: Pharmaceutical Preparations Containing Cyclodextrin Derivatives
View Opportunity for a Cooperative Research and Development Agreement (CRADA) and Licensing Opportunity for Testosterone Bucyclate In view of the high priority for developing and commercializing testosterone bucyclate, all proposals must be received no later than September 5, 1995 for priority consideration.
View Prospective Grant of Exclusive License: Polysaccharide-Protein Conjugates